MBX Biosciences, Inc. MBX

53.63 (1.76) (3.18%) as of 25 Sep
Market cap
$2.7B
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

32.95 24.62 30.79 18.08
Net Debt/EBITDA
16.40 14.52 16.18 10.25
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
1.00 0.83 0.86 0.61
Capex/Depreciation
(7.98) (13.22) (6.83) (11.41)
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.64) (0.52) (0.44) (0.49)
Cash per Share
11.45 10.24 9.45 8.78
Shareholders Equity per Share
11.33 10.11 9.40 8.59
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
11.33 10.11 9.40 8.59
Free Cash Flow
(21.93) (19.09) (20.64) (23.52)
Working Capital
385.44 366.04 433.97 404.20
Capital Expenditures
(0.40) (0.79) (0.44) (0.90)
Net Current Asset Value
384.96 365.62 433.59 401.49
Other line items
Quick Ratio
32.47 24.12 30.20 17.69
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.63) (0.50) (0.43) (0.47)
Capex per Share
(0.01) (0.02) (0.01) (0.02)
Average Payables
4.39 4.16 5.61 5.06
Average Assets
341.24 326.84 349.31 333.72
Average Common Equity
329.45 313.33 336.59 314.39
Capex to Sales
0.00 0.00 0.00 0.00
Net Profit Margin
0.00% 0.00% 0.00% 0.00%

Fold the line items

Columns are period end dates